Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed Tumors.
Where this comes from
- Record sourced from PubMed, PMID 31806771.
- Also identified by DOI 10.2967/jnumed.119.231068 and PMC identifier 7262227.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although the incidence of de novo neuroendocrine prostate cancer (PC) is rare, recent data suggest that low expression of prostate-specific membrane antigen (PSMA) is associated with a spectrum of neuroendocrine hallmarks and androgen receptor (AR) suppression in PC. Previous clinical reports indicate that PCs with a phenotype similar to neuroendocrine tumors can be more amenable to imaging by <sup>18</sup>F-FDG than by PSMA-targeting radioligands. In this study, we evaluated the association between neuroendocrine gene signature and <sup>18</sup>F-FDG uptake-associated genes including glucose transporters (GLUTs) and hexokinases, with the goal of providing a genomic signature to explain the reported <sup>18</sup>F-FDG avidity of PSMA-suppressed tumors. <b>Methods:</b> Data-mining approaches, cell lines, and patient-derived xenograft models were used to study the levels of 14 members of the <i>SLC2A</i> family (encoding GLUT proteins), 4 members of the hexokinase family (genes <i>HK1</i>-<i>HK3</i> and <i>GCK</i>), and PSMA (<i>FOLH1</i> gene) after AR inhibition and in correlation with neuroendocrine hallmarks. Also, we characterize a neuroendocrine-like PC (NELPC) subset among a cohort of primary and metastatic PC samples with no neuroendocrine histopathology. We measured glucose uptake in a neuroendocrine-induced in vitro model and a zebrafish model by nonradioactive imaging of glucose uptake using a fluorescent glucose bioprobe, GB2-Cy3. <b>Results:</b> This work demonstrated that a neuroendocrine gene signature associates with differential expression of genes encoding GLUT and hexokinase proteins. In NELPC, elevated expression of <i>GCK</i> (encoding glucokinase protein) and decreased expression of <i>SLC2A12</i> correlated with earlier biochemical recurrence. In tumors treated with AR inhibitors, high expression of <i>GCK</i> and low expression of <i>SLC2A12</i> correlated with neuroendocrine histopathology and PSMA gene suppression. GLUT12 suppression and upregulation of glucokinase were observed in neuroendocrine-induced PC cell lines and patient-derived xenograft models. A higher glucose uptake was confirmed in low-PSMA tumors using a GB2-Cy3 probe in a zebrafish model. <b>Conclusion:</b> A neuroendocrine gene signature in neuroendocrine PC and NELPC associates with a distinct transcriptional profile of GLUTs and hexokinases. PSMA suppression correlates with GLUT12 suppression and glucokinase upregulation. Alteration of <sup>18</sup>F-FDG uptake-associated genes correlated positively with higher glucose uptake in AR- and PSMA-suppressed tumors. Zebrafish xenograft tumor models are an accurate and efficient preclinical method for monitoring nonradioactive glucose uptake.
Medical subject headings
- Fluorodeoxyglucose F18
- Glucose Transport Proteins, Facilitative
- Glutamate Carboxypeptidase II
- Hexokinase
- Prostatic Neoplasms